As shown in Table 2, the participants’ objective response status differed according to the CAR T cell immunotherapy administered, Eastern Cooperative Oncology Group Performance Status (ECOG PS) scores, lactate dehydrogenase (LDH) levels, tumor size (<7.0 cm or ≥7.0 cm), and the presence of a TP53 mutation. Here, TP53 is linked to neoplasm.